Quick Sticks announces national distribution
DALLAS — A line of flavored powdered packets aimed at hypoglycemia sufferers has made its way to stores nationwide.
Quick Sticks, a quick-dissolve glucose supplement developed for hypoglycemia sufferers that require a easier way to treat symptoms of low blood sugar, now will be available at Walmart and Walgreens stores stores across the United States. Launched last year, the product initially was available at select Kroger and H-E-B stores, as well as Amazon.com.
"We’re very excited about making Quick Sticks available nationwide to those who face the everyday challenges of hypoglycemia," said Cole Egger, founder and President of QS Holdings, the maker of Quick Sticks. "We’ve been overwhelmed with positive feedback from our fans saying they love the product, so this is definitely a much-anticipated launch."
Available in sour apple and watermelon flavors, Quick Sticks carry a suggested retail price range from $5.24 to $6.49 per 12-count box.
Genzyme drug for Gaucher disease reduces enlarged spleen size in trial
CAMBRIDGE, Mass. — An experimental drug for treating a rare genetic disease appears effective, according to a late-stage clinical trial.
Sanofi subsidiary Genzyme said Tuesday that the drug eliglustat tartrate was effective in improving spleen size in previously untreated patients with Type 1 Gaucher disease in the phase-3 "Engage" trial. Gaucher disease is an enzyme deficiency disorder that affects fewer than 10,000 people worldwide and causes fat cells to collect around the spleen, liver and bone marrow. Patients with the disease may experience enlargement of the spleen and liver, anemia, excessive bleeding and bruising, bone disease and other symptoms.
"The efficacy and safety data from our Engage trial are consistent with what were observed in our phase-2 study, continuing to suggest that eliglustat tartrate is a potent, well-tolerated oral compound that may become a meaningful option for patients and physicians," Genzyme president and CEO David Meeker said. "The development of eliglustat tartrate has been underway for more than a decade and is the largest clinical program ever focused on Gaucher disease, demonstrating our ongoing commitment to innovation on behalf of this community."
The company has enrolled more than 370 patients for various studies of the drug. Top-line data from the second phase-3 trial, "Encore," are expected early next year.
Yankee Candle unveils holiday lineup
SOUTH DEERFIELD, Mass. — Yankee Candle has announced the launch of three new fragrances for the holidays.
New Peppermint bark, pine cone and lime, and Red Velvet scents are inspired by nostalgic family recipes, the company said.
"Our new holiday fragrances evoke fond childhood memories of baking during the holiday time and celebrating the season with family and friends," Yankee Candle EVP brand, design and innovation Hope Margala Klein said. "These new fragrances will add to the comfort and warmth of our customers homes and also make the perfect gift for everyone on their list."
The new holiday fragrances now are available for purchase for a suggested retail price range of $1.99 to $27.99, depending on size.